Mackenzie Financial’s Vaxcyte PCVX Stock Holding History

Mackenzie Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,174	Closed	-$325K	–	1670
2025 Q4	$325K	Sell	7,174 -829	-10%	-$37.1K	﹤0.01%	1349
2025 Q3	$288K	Hold	8,003	–	–	﹤0.01%	1431
2025 Q2	$260K	Buy	+8,003	New	+$262K	﹤0.01%	1456
2025 Q1	–	Sell	-5,071	Closed	-$415K	–	1768
2024 Q4	$415K	Sell	5,071 -303	-6%	-$30.1K	﹤0.01%	1250
2024 Q3	$614K	Buy	5,374 +2,004	+59%	+$181K	﹤0.01%	970
2024 Q2	$254K	Sell	3,370 -675	-17%	-$45.9K	﹤0.01%	1240
2024 Q1	$276K	Buy	4,045 +102	+3%	+$7.06K	﹤0.01%	1206
2023 Q4	$248K	Sell	3,943 -1,813	-31%	-$94.2K	﹤0.01%	1239
2023 Q3	$273K	Hold	5,756	–	–	﹤0.01%	1172
2023 Q2	$283K	Buy	+5,756	New	+$273K	﹤0.01%	1189
2023 Q1	–	Sell	-4,479	Closed	-$215K	–	1589
2022 Q4	$215K	Buy	+4,479	New	+$176K	﹤0.01%	1220

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mackenzie Financial's PCVX Position: Q1 2026 in Review

Mackenzie Financial sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 7,174 shares — an estimated $325K sold.

Mackenzie Financial first reported a position in PCVX in Q4 2022 and held it in 11 quarters. The position peaked at $614K in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Mackenzie Financial reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
Mackenzie Financial sold 7,174 Vaxcyte shares in Q1 2026, an estimated $325K.
Mackenzie Financial first reported a position in Vaxcyte in Q4 2022 and held it in 11 quarters.
Mackenzie Financial's Vaxcyte position peaked at $614K in Q3 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.